**Background of FGF14 Antibody**
The fibroblast growth factor 14 (FGF14) is a member of the intracellular FGF family, primarily expressed in the central nervous system, particularly in cerebellar Purkinje cells, hippocampal neurons, and cortical regions. It plays a critical role in regulating neuronal excitability, synaptic plasticity, and ion channel function by interacting with voltage-gated sodium channels (Nav1.6) and other signaling molecules. Dysregulation of FGF14 is linked to neurological disorders, including spinocerebellar ataxia type 27B (SCA27B), epilepsy, and cognitive impairments.
FGF14 antibodies are essential tools for studying its expression, localization, and functional mechanisms. These antibodies, often monoclonal or polyclonal, are validated for applications such as Western blotting, immunohistochemistry, and immunofluorescence to detect FGF14 in tissue samples or cell lines. Researchers use them to explore FGF14's role in disease models, such as ataxia or seizure disorders, and to assess its interaction partners or post-translational modifications. Specificity and affinity are critical, requiring validation via knockout controls or peptide-blocking assays.
Recent studies highlight FGF14 antibodies in biomarker discovery and therapeutic targeting, given their potential to modulate FGF14-pathway activity in neurodegenerative conditions. Advances in antibody engineering, such as recombinant or phospho-specific variants, further enhance their utility in dissecting FGF14's complex roles in health and disease.